Bacopa vs Cerebrolysin for memory
Short answer: For memory, users rate them about the same: 94% report improvement with Bacopa (133 reports) and 96% with Cerebrolysin (24 reports).
Bacopa has 16 meta-analyses and 17 randomized trials on PubMed; Cerebrolysin has 30 and 60.
Based on 676 reports about Bacopa and 196 about Cerebrolysin. Not medical advice.
| Bacopa Supplement | Cerebrolysin Peptide | |
|---|---|---|
| User score | 48 | 49 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 56% | 75% |
| Reports | 676 | 196 |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 16 / 17 | 30 / 60 |
| Mainly used for | ||
| Focus % reporting improvement | 83% (59) | 90% (21) |
| Energy % reporting improvement | 32% (31) | 88% (8) |
| Sleep % reporting improvement | 73% (33) | 100% (5) |
| Anxiety % reporting improvement | 91% (87) | 89% (9) |
| Mood % reporting improvement | 45% (67) | 90% (20) |
| Memory % reporting improvement | 94% (133) | 96% (24) |
| Recovery % reporting improvement | — | 100% (3) |
| Pain & inflammation % reporting improvement | — | 100% (2) |
| Digestion % reporting improvement | 0% (3) | — |
| Libido % reporting improvement | 29% (7) | — |
| Common side effects | fatigue, drowsiness, demotivation, brain fog | brain fog, fatigue, headache, tingling |
| Typical dose reported | before bed | Not listed |
Caffeine enhances attention and executive functions. Together, the results from the compiled studies highlight the nootropic effects and the inconsistencies regarding PDNs that require further research.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2021.2021137.
Crit Rev Food Sci Nutr, 2023 ↗“Bacopa monnieri is the best against my brain fog, I grow my own. But it does not give more energy, just good mental focus.”
Ginkgo biloba extracts have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low. Future trials should focus on a single VCI subtype, prioritize interventions with a strong mechanistic rationale, standardize diagnostic criteria, ensure adequate power for chosen outcomes, test against placebo, and implement FAIR data sharing to accelerate therapeutic discovery.
Alzheimers Dement, 2025 ↗“Cerebrolysin is by far the best nootropic I have ever used...my memory, recall ability, sensitivity to music, observance over my emotions, thinking faculties have all improved to a noticeable amount.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate